Key Players
Competitive Landscape
Key players in BCMA targeted therapies market include diversified pharmaceutical groups, cell-therapy partnerships, antibody-platform owners and clinical-stage BCMA developers.
Capital has moved in two directions since 2025, into launch access for approved antibodies and ownership of late-stage cell-therapy assets. GSK secured permanent J-code J9053 for BLENREP in July 2026 to standardize United States billing across hospital outpatient settings. Gilead completed its USD 7.8 billion Arcellx acquisition in April 2026 and gained full control of the anito-cel program. Price remains relevant across approved modalities, yet hospitals sort companies first by treatment-line eligibility and delivery reliability alongside monitoring burden.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| GSK, permanent J-code J9053 for BLENREP, July 2026 | Hospital oncology programs need predictable billing before routine outpatient use. | Competition now extends from approval into reimbursement execution. | Coding support can widen adoption across hospital outpatient sites. |
| Gilead Sciences, completed USD 7.8 billion Arcellx acquisition, April 2026 | Cell-therapy sponsors seek control of manufacturing and launch economics. | Late-stage BCMA assets are consolidating under commercial cell-therapy platforms. | Integrated manufacturing and commercialization can support anito-cel launch revenue. |
| Regeneron Pharmaceuticals, FDA accelerated approval for LYNOZYFIC, July 2025 | Heavily treated patients need stocked options without personalized manufacturing. | Bispecific antibodies are widening competition against autologous CAR-T products. | Repeat dosing supports revenue through qualified hematology centers. |
Johnson & Johnson, Bristol Myers Squibb, Pfizer Inc., AbbVie Inc. and Legend Biotech Corporation compete through approved-line access, clinical depth and manufacturing execution beyond the three actions mapped above.
Source: Future Market Insights, BCMA Targeted Therapies and Blood Cancer Treatment Market Reports, 2026-2036.
Johnson & Johnson and Gilead together cover approved bispecific antibodies, commercial CAR-T therapy, late-stage cell therapy and global manufacturing support.
Who leads the BCMA targeted therapies market?
Johnson & Johnson leads on approved modality breadth through CARVYKTI and TECVAYLI across cellular and stocked treatment pathways. Legend Biotech supports CARVYKTI development and commercialization through the established global collaboration with Johnson & Johnson.
Which companies have approved BCMA products in the United States?
Johnson & Johnson, Bristol Myers Squibb, GSK plc, Pfizer Inc. and Regeneron Pharmaceuticals hold approved United States BCMA products. Legend Biotech participates through CARVYKTI while AbbVie and Gilead remain focused on investigational programs worldwide.
Which companies provide cellular therapies and stocked antibody products?
Johnson & Johnson, Bristol Myers Squibb, Legend Biotech and Gilead compete through patient-specific CAR-T programs worldwide. GSK plc, Pfizer Inc., Regeneron Pharmaceuticals and AbbVie address stocked antibody or antibody drug conjugate pathways.
Which companies serve North America, Europe and Japan?
Johnson & Johnson, Bristol Myers Squibb and Legend Biotech support approved BCMA cell therapies across North America, Europe and Japan. GSK and Pfizer maintain multi-region antibody programs while Regeneron and AbbVie extend clinical or commercial coverage across selected markets.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Johnson & Johnson | USA, Europe and Japan | CARVYKTI CAR-T therapy and TECVAYLI bispecific antibody; March 2026 combination approval. |
| Bristol Myers Squibb | USA, Europe and Japan | ABECMA autologous CAR-T therapy for relapsed multiple myeloma. |
| GSK plc | USA and Japan | BLENREP antibody drug conjugate; permanent J-code assigned in July 2026. |
| Pfizer Inc. | Global | ELREXFIO bispecific antibody; positive Phase III result reported in April 2026. |
| AbbVie Inc. | Global clinical development | Etentamig BCMA x CD3 bispecific antibody in Phase III CERVINO. |
| Regeneron Pharmaceuticals, Inc. | USA and Europe | LYNOZYFIC bispecific antibody; FDA accelerated approval in July 2025. |
| Legend Biotech Corporation | USA, Europe and Japan | CARVYKTI development and commercialization with Johnson & Johnson. |
| Gilead Sciences, Inc. | United States filing and global development | Anito-cel CAR-T program within Kite; Arcellx acquisition completed in April 2026. |
Research Methodology
The companies here show how the market is structured rather than ranking corporate performance across unrelated oncology portfolios. A company appears only where current verifiable evidence shows it supplies BCMA-directed therapies or advances a directly relevant clinical program. Evidence comes from official company websites and dated corporate releases that identify products and active regions. Regulatory records and filings establish approval status, ownership and legal identity for each listed therapy program. Technology shares are FMI estimates, with the 47.0% BCMA CAR-T cell therapy figure applying to 2026.
